Developing a New Class of Intracellular Targeted Therapeutics

Ashvattha Therapeutics are harnessing the power of Hydroxyl Dendrimers (HDs) to create a new class of precision medicine to heal patients.

Welcome to Ashvattha

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care.

We are developing immune-oncology HD therapeutics in serious unmet needs leveraging our ability to target tumor associated macrophages (TAMs)

We have designed and optimized an HDT that precisely targets reactive macrophages and retinal pigment epithelial cells (RPEs) after systemic administration

OP-101 selectively targets pro-inflammatory macrophages and microglia responsible for excessive cytokine production in severe COVID-19 patients

Latest News

Neurologists test novel compound for lung and brain injury in severe COVID-19 patients (UT Health News)

Neurologists are researching whether a novel immunomodulatory treatment, OP-101, an investigational compound developed by Ashvattha Therapeutics, can dampen lung and brain injury in hospitalized COVID-19 patients through a clinical trial at The University of Texas Health Science Center at Houston.

Ashvattha Therapeutics Selected to Present Late-Breaking Poster Presentation on Use of Novel Hepatocyte Targeted Hydroxyl Dendrimer Therapeutic at The Liver Meeting 2020

shvattha Therapeutics announced data from a late-breaking presentation at The Liver Meeting Digital Experience 2020 of the American Association for the Study of Liver Diseases (AASLD), held virtually November 13-16, 2020.

Ashvattha Therapeutics Announces Formation of Scientific Advisory Board

Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.

Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020

Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.